Unlock instant, AI-driven research and patent intelligence for your innovation.

Recombinant HPV16L2 protein vaccine and preparation method thereof

A technology of HPV16L2 and protein vaccine, applied in the field of recombinant protein preparation, can solve the problems of decreased immune effect of vaccine, increased dose of vaccinated protein, increased allergy of vaccinated individuals, etc., and achieves good preventive effect, improved titer, and high immunogenicity Effect

Inactive Publication Date: 2013-09-25
BEIJING UNIV OF TECH
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Recent studies have shown that mixed preparations of different types of HPV L1 VLPs will compete with each other during immunization, resulting in a decline in the overall immune effect of the vaccine (Ting Zhang, Vaccine, 2010, 28(19):3479-3487) and many The mixed preparation of VLPs increases the dose of vaccination protein and increases the chance of allergy in vaccinated individuals
A large number of experiments have confirmed that the N-terminal of the HPV16L2 protein has a cross-neutralizing epitope that neutralizes various HPV genotypes, and is a promising candidate for cervical cancer vaccines (Kawana K, Virology, 1998, 245:353-359), however , its low immunogenicity restricts the further application of the vaccine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant HPV16L2 protein vaccine and preparation method thereof
  • Recombinant HPV16L2 protein vaccine and preparation method thereof
  • Recombinant HPV16L2 protein vaccine and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Recombinant HPV16L2 protein vaccine, which contains the N-terminal polypeptide fragment of HPV16L2 (HPV16L2 Ne) and transduction domain polypeptide (PTD) with membrane-penetrating activity.

[0029] The N-terminal polypeptide fragment of HPV16L2 (HPV16L2Ne) is an HPV16L2 1-88aa polypeptide fragment or an HPV16L2 1-200aa polypeptide fragment; the nucleotide sequence encoding the HPV16L2 1-88aa polypeptide fragment is SEQ ID No in the sequence listing: 1. The nucleotide sequence encoding the HPV16L2 1-200aa polypeptide fragment is SEQ ID No: 2 in the sequence listing.

[0030] The nucleotide sequence encoding the transduction domain polypeptide (PTD) with membrane-penetrating activity is SEQ ID No: 3 in the sequence listing; the amino acid sequence of the transduction domain polypeptide (PTD) with membrane-penetrating activity It is SEQ ID No: 4 in the sequence listing.

[0031] The protein vaccine has two forms: the protein vaccine has two forms: one is HPV16L2Ne-PTD fu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of recombinant protein preparation and relates to a recombinant HPV16L2 protein vaccine and a preparation method thereof. The protein vaccine contains N-end polypeptide fragments (HPV16L2Ne) of HPV16L2 and protein transduction domain polypeptide (PTD) with transmembrane activity. The protein vaccine has two manners: one is HPV16L2Ne-PTD fusion protein, and the other is a mixture of HPV16L2Ne and PTD which are mixed according to equal proportion. Due to synergistic effect of transmembrane activity of PTD polypeptide and immunogenicity of HPV16L2 protein, immunogenicity is high. The preparation method is used for preparing the recombinant HPV16L2 protein vaccine, titer for generating a neutralizing antibody is remarkably improved, and good prevention effect is obtained.

Description

technical field [0001] The invention belongs to the field of recombinant protein preparation, and relates to a recombinant HPV16L2 protein vaccine and a preparation method thereof. The protein vaccine contains an HPV16L2 N-terminal polypeptide fragment (HPV16L2 Ne) and a transduction domain polypeptide (PTD) with transmembrane activity. Background technique [0002] Human papillomavirus (HPV) is a non-enveloped closed-circle double-stranded DNA virus belonging to the Papovaviridae family. It is now clear that the persistent infection of high-risk HPV such as HPV16 and 18 is closely related to the occurrence of cervical cancer, and has been identified as the main cause of cervical cancer, among which HPV16 is the most common (Bosch F X, J Natl Cancer Inst, 1995, 87: 796–802.). [0003] The Chinese patent "A Therapeutic Vaccine for Human Cervical Cancer (Patent No.: ZL200810112765.9)" discloses a therapeutic vaccine for human cervical cancer. The active ingredient of the vacc...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/12A61P31/20A61P35/00C12N15/70C07K19/00C07K14/025
Inventor 曾毅周玉柏郭艳涛李泽琳
Owner BEIJING UNIV OF TECH